[Economic aspects of allergies: status and prospects for Austria].
According to epidemiological studies there has been an increase of allergic diseases and corresponding costs. Health economics analyses intend to offer decision guidance towards a more efficient and effective resource distribution, in the conflicting relationship of medicine and economics. In analogy with the "Global Initiative for Asthma (GINA)-study", one arrives at costs of Euro 227.7-455.4 million for the Austrian health system in 2004 for asthma. Direct costs of allergies in general are in part available from health insurance carriers. Between 1998 and 2005 the number of nasal preparations and antiobstructive therapies prescribed rose by 15% and 50% respectively, whilst the costs of these drugs dramatically increased by 96% and 70% respectively. Expenditure on anti-histamines rose by 31% between 2002 and 2004, whereas costs of topical and systemic anti-allergic drugs remained constant. Costs of allergies also include additional costs carried by the individuals affected, which must be added to those covered by the national health insurance carriers. Furthermore, patients with allergies more frequently turn to alternative and complimentary medicine to treat their condition (above all homeopathic remedies, massages and ointments) than people not suffering from allergies. Indirect costs due to allergies are, for instance, those caused by sick leave and loss of productivity. A continual systematic evaluation of available data on allergies in Austria could contribute to more effective implementation of medicines.
Stein
Viktoria
V
Institut für Sozialmedizin, Centre for Public Health, Medizinische Universität Wien, Wien, Osterreich. katharina.v.stein@meduniwien.ac.at
Dorner
Thomas
T
Lawrence
Kitty
K
Kunze
Michael
M
Rieder
Anita
A
D000328:Adult; D000368:Aged; D000707:Anaphylaxis / Q000191:economics; D000799:Angioedema / Q000191:economics; D001249:Asthma / Q000191:economics; D001317:Austria; D002648:Child; D000529:Complementary Therapies / Q000191:economics; D003362:Cost-Benefit Analysis; D003877:Dermatitis, Contact / Q000191:economics; D016527:Drug Costs; D004485:Eczema / Q000191:economics; D005260:Female; D017048:Health Care Costs; D006801:Humans; D006967:Hypersensitivity / Q000191:economics*; D007348:Insurance, Health / Q000191:economics; D008297:Male; D008875:Middle Aged; D018582:Sick Leave / Q000191:economics*; D014581:Urticaria / Q000191:economics